stockrowKiniksa Pharmaceuticals International, plc (KNSA) vs Liquidia Corporation (LQDA)
- Kiniksa Pharmaceuticals International, plc KNSA 88.50 −7.93%
- Liquidia Corporation LQDA 44.69 −5.68%
Kiniksa Pharmaceuticals International, plc and Liquidia Corporation are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $6.9B against $4.0B — 1.7× the size. Liquidia Corporation trades at the lower P/E: 28.5× against 62.1×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against 58.2%. Liquidia Corporation has the higher net margin (30.7% vs 11.6%) and the higher return on invested capital (121.1% vs 57.7%). Across the 20 metrics below, Liquidia Corporation leads on 13 and Kiniksa Pharmaceuticals International, plc on 7.
Valuation
Profitability
| Metric | KNSA | LQDA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 90.16% | 92.54% | 53.51% |
| Operating margin | 13.79% | 37.39% | 0.00% |
| Net margin | 11.58% | 30.74% | (2.45%) |
| Free cash flow margin | 20.85% | 33.42% | 0.00% |
| Return on equity | 17.59% | 131.82% | (0.80%) |
| Return on assets | 12.92% | 35.57% | (1.67%) |
| Return on invested capital | 57.65% | 121.05% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack